1 to 3 of 3 literature results

• Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.

  Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commerc…

  Authors: Laure Escoubet-Lozach, I-Lin Lin, Kristen Jensen-Pergakes, Helen A Brady, Anita K Gandhi, Peter H Schafer, George W Muller, Peter J Worland, Kyle W H Chan, Dominique Verhelle

  Source: Cancer research. 2009 Sep 15

  View Full Text

• Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.

  Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often e…

  Authors: Dominique Verhelle, Laura G Corral, Kevin Wong, Jessica H Mueller, Laure Moutouh-de Parseval, Kristen Jensen-Pergakes, Peter H Schafer, Roger Chen, Emilia Glezer, Gregory D Ferguson,…

  Source: Cancer research. 2007 Jan 15

  View Full Text

• SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF.

  Bone metabolism requires tightly coupled activities exhibited by two unique cell populations, the bone-resorbing osteoclasts and the bone-forming oste…

  Authors: May S Kung Sutherland, Stephanie G Lipps, Nandita Patnaik, Leah M Gayo-Fung, Sak Khammungkune, Weilin Xie, Helen A Brady, Miguel S Barbosa, David W Anderson, Bernd Stein

  Source: Cytokine. 2003 Jul

  View Full Text